Marking Rare Disease Day, FDA and patient group launch collaboration
AstraZeneca’s biologics division MedImmune is to spin out a new standalone biotech to develop six early-stage inflammation and autoimmunity programmes.
Lantern Pharma, a pharma company which uses artificial intelligence to develop shelved oncology drugs has joined Genomics England’s groundbreaking industry partnership.
Tesaro is to combine its PARP-inhibitor drug Zejula with Roche’s PD-L1 immunotherapy Tecentriq in clinical trials for metastatic bladder cancer.
New phase 3b trial results show Lilly’s Trulicity combined with an SGLT2 inhibitor failed to show any benefits above and beyond Trulicity’s blood glucose lowering.